BioEcho Life Sciences develops novel kits for the isolation and processing of DNA and RNA. The new EchoCLEAN CleanUp kits for rapid single-step purification of RNA or DNA samples with removal of any residual denaturating salts or organic solvents increase the reliability in PCR and NGS analysis.
In March, the 9th edition of the "European Biotechnology Science & Industry Guide" will be published and distributed at BIO Europe Spring conference 2019 in Vienna. The B2B handbook presents companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing an ideal medium with which new customers and investors can find you. The previous edition can be found here.
Medigene is developing the next generation of effective TCR cell therapies aimed at establishing better control over cancer at reasonable production cost.
CYPs have a number of disadvantages, including low stability or inactivity. The Austrian Centre of Industrial Biotechnology (acib), together with an consortium within the EU-project ROBOX, created lyophilised CYP biocatalysts that have proven to be very promising for a variety of industrial applications for the pharma, flavour and fragrance, and material science industries.
Vetter strikes out on new pathways to further develop the injection process.
CDMO launches the Vetter Open Innovation Challenge under the slogan Injection 2.0
BioEcho GmbH develops kits for the isolation and processing of DNA and RNA with a rapidly expanding portfolio. With expertise and passion, we overcome the limitations of common nucleic acid extraction with pioneering methods such as the proprietary Echolution single-step technology.
TRIANNIs antibody discovery platform, The Trianni Mouse, represents best-in-class technology for efficient generation of fully-human monoclonal antibodies.
The European Biotechnology Science & Industry Guide 2018 provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry.
Serialisation dominates the discussion about how to implement the Falsified Medicines Directive (2011/62/EU). However, to meet the February 2019 deadline, companies must also pay attention to the second required safety feature: the anti-tampering device. The use of tamper-evident labels is widespread. But beware! There are many challenges associated with these popular tamper-evident devices.
The brand new 19th Guide to German Biotech Companies 2018 provides a wealth of information on companies and organisations offering products and services in the life sciences.